Background: There is a strong association between obstructive sleep apnea and hypertension, but the effects of obstructive sleep apnea symptoms on the risk of incident hypertension are not well documented. The aim of this prospective study was to examine whether snoring and sleepiness are associated with incident hypertension., Methods: Data from the French population-based CONSTANCES cohort were analyzed. Normotensive participants, aged 18 to 69 years, were included between 2012 and 2016 and screened for snoring, morning fatigue, and daytime sleepiness in 2017 using items of the Berlin Questionnaire. We used Cox models, adjusted for multiple potential confounders, including body mass index, baseline blood pressure, sleep duration, and depressive symptoms, to compute hazards ratios of incidentally treated hypertension., Results: Among 34 727 subjects, the prevalence of self-reported habitual snoring, morning fatigue, and excessive daytime sleepiness (≥3× a week for each) was 23.6%, 16.6%, and 19.1%, respectively. During a median follow-up of 3.1 years (interquartile range, 3.0-3.5), the incidence of treated hypertension was 3.8%. The risk of de novo treated hypertension was higher in participants who reported habitual snoring (adjusted hazard ratio, 1.17 [95% CI, 1.03-1.32]) and excessive daytime sleepiness (adjusted hazard ratio, 1.42 [95% CI, 1.24-1.62]), and increased with the weekly frequency of symptoms, with a dose-dependent relationship ( P trend ≤0.02 for all symptoms)., Conclusions: Self-reported snoring and excessive daytime sleepiness are associated with an increased risk of developing hypertension. Identification of snoring and daytime sleepiness may be a useful public health screening tool in primary care for hypertension prevention., Competing Interests: All authors have completed the International Committee of Medical Journal Editors uniform disclosure form. P. Balagny reported no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. E. Vidal-Petiot reported honoraria for lectures from Servier and financial support for attending meetings from Servier outside of the submitted work and no other relationships or activities that could appear to have influenced the submitted work. S. Kab reported no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. J. Frija has received unrestricted research grants from LVL medical, payments for lectures from SOS oxygène, support for attending meeting from LVL medical, Vitalaire, ADEP assistance and SOS oxygène, and fiduciary role in Société Française de Recherche et Médecine du Sommeil, and no other relationships or activities that could appear to have influenced the submitted work. P.G. Steg has received grants from Amarin, AstraZeneca, Bayer, Sanofi, and Servier; consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb/Myokarddia, Merck, Novo-Nordisk and Regeneron, Steering Comitee or Critical Event Committee from Amarin, AstraZeneca, Bayer, Boerhriger Ingelheim, Bristo-Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, and Servier; payments for lectures from AstraZeneca, Novartis, and Novo-Nordisk; support for attending meetings from AstraZeneca and participation on a Data Safety Monitoring Board or Advisory Board from Servier, Sanofi, Population Health Research Institute and Monash University; and no other relationships or activities that could appear to have influenced the submitted work. M. Goldberg reported no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. M. Zins reported no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. M.P. d’Ortho has received unrestricted research grants from Asten Santé; consultant fees from ResMed; speaker fees from Resmed and LVL; and traveling grants from ADEP Assistance, Vitalaire, and LVL; stock options from Digital Medical Hub Société par Action Simplifiée; and no other relationships or activities that could appear to have influenced the submitted work. E. Wiernik reported no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.